caa a22 4500 445338199 CHVBK 20180317142802.0 cr unu---uuuuu 170323e20110201xx s 000 0 eng 10.1245/s10434-010-1319-2 doi (NATIONALLICENCE)springer-10.1245/s10434-010-1319-2 Effects of Intraperitoneal Chemotherapy with Mitomycin C on the Prevention of Peritoneal Recurrence in Colorectal Cancer Patients with Positive Peritoneal Lavage Cytology Findings [Elektronische Daten] [Shingo Noura, Masayuki Ohue, Tatsushi Shingai, Shingo Kano, Hiroaki Ohigashi, Masahiko Yano, Osamu Ishikawa, Akemi Takenaka, Kohei Murata, Masao Kameyama] Background: The detection of intraperitoneal free cancer cells in colorectal cancer (CRC) patients is associated with a poorer prognosis. The aim of this study was to investigate the effects of intraperitoneal chemotherapy (IPC) with mitomycin C (MMC) on preventing peritoneal recurrence in CRC patients with positive peritoneal lavage cytology findings. Methods: A total of 52 CRC patients who had no clinically confirmed peritoneal dissemination and whose status of peritoneal lavage cytology was positive were investigated. Conventional peritoneal lavage cytology was performed. Overall, 31 of the 52 patients (59.6%) were administered IPC with MMC. Before closure of the abdomen, 4 silicon catheters were inserted into peritoneal cavity. After closure, the perfusate (diluting 20mg MMC with 500ml saline) was instilled from the catheter, and all catheters were clumped. All catheters were opened 1 h later. Results: The mean follow-up period was 83.1months. According to univariate analyses of all 52 patients and the subgroup of 36 patients with stage II or III tumors, patients with IPC had a significantly better peritoneal recurrence-free survival and cancer-specific survival than patients who did not receive IPC (P<0.005). In multivariate analysis, IPC remained an independent prognostic factor for peritoneal recurrence-free survival in all patients. Conclusions: It appears that IPC with MMC is an effective treatment to prevent peritoneal recurrence and prolong the cancer-specific survival in CRC patients without peritoneal dissemination, but who have positive peritoneal lavage cytology. It is necessary to verify the effectiveness of IPC with MMC in a prospective trial. Society of Surgical Oncology, 2010 Noura Shingo Department of Surgery, Osaka Medical Center for Cancer and Cardiovascular Diseases, Osaka, Japan aut Ohue Masayuki Department of Surgery, Osaka Medical Center for Cancer and Cardiovascular Diseases, Osaka, Japan aut Shingai Tatsushi Department of Surgery, Osaka Medical Center for Cancer and Cardiovascular Diseases, Osaka, Japan aut Kano Shingo Department of Surgery, Osaka Medical Center for Cancer and Cardiovascular Diseases, Osaka, Japan aut Ohigashi Hiroaki Department of Surgery, Osaka Medical Center for Cancer and Cardiovascular Diseases, Osaka, Japan aut Yano Masahiko Department of Surgery, Osaka Medical Center for Cancer and Cardiovascular Diseases, Osaka, Japan aut Ishikawa Osamu Department of Surgery, Osaka Medical Center for Cancer and Cardiovascular Diseases, Osaka, Japan aut Takenaka Akemi Department of Cytology, Osaka Medical Center for Cancer and Cardiovascular Diseases, Osaka, Japan aut Murata Kohei Department of Surgery, Suita Municipal Hospital, Suita, Japan aut Kameyama Masao Department of Surgery, Bell Land General Hospital, Sakai, Japan aut Annals of Surgical Oncology Springer-Verlag 18/2(2011-02-01), 396-404 1068-9265 18:2<396 2011 18 10434 https://doi.org/10.1245/s10434-010-1319-2 text/html Onlinezugriff via DOI 1 research-article jats NATIONALLICENCE 856 40 https://doi.org/10.1245/s10434-010-1319-2 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Noura Shingo Department of Surgery, Osaka Medical Center for Cancer and Cardiovascular Diseases, Osaka, Japan aut NATIONALLICENCE 700 1- Ohue Masayuki Department of Surgery, Osaka Medical Center for Cancer and Cardiovascular Diseases, Osaka, Japan aut NATIONALLICENCE 700 1- Shingai Tatsushi Department of Surgery, Osaka Medical Center for Cancer and Cardiovascular Diseases, Osaka, Japan aut NATIONALLICENCE 700 1- Kano Shingo Department of Surgery, Osaka Medical Center for Cancer and Cardiovascular Diseases, Osaka, Japan aut NATIONALLICENCE 700 1- Ohigashi Hiroaki Department of Surgery, Osaka Medical Center for Cancer and Cardiovascular Diseases, Osaka, Japan aut NATIONALLICENCE 700 1- Yano Masahiko Department of Surgery, Osaka Medical Center for Cancer and Cardiovascular Diseases, Osaka, Japan aut NATIONALLICENCE 700 1- Ishikawa Osamu Department of Surgery, Osaka Medical Center for Cancer and Cardiovascular Diseases, Osaka, Japan aut NATIONALLICENCE 700 1- Takenaka Akemi Department of Cytology, Osaka Medical Center for Cancer and Cardiovascular Diseases, Osaka, Japan aut NATIONALLICENCE 700 1- Murata Kohei Department of Surgery, Suita Municipal Hospital, Suita, Japan aut NATIONALLICENCE 700 1- Kameyama Masao Department of Surgery, Bell Land General Hospital, Sakai, Japan aut NATIONALLICENCE 773 0- Annals of Surgical Oncology Springer-Verlag 18/2(2011-02-01), 396-404 1068-9265 18:2<396 2011 18 10434 Metadata rights reserved Springer special CC-BY-NC licence nationallicence BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-springer